Reactive oxygen species alter dopaminergic and purinergic signaling and microglia physiology in the nucleus accumbens

Insights

Microglia in the brain respond to adenosine triphosphate (ATP) more readily than dopamine (DA). Immune activation by lipopolysaccharide (LPS) alters microglia and increases DA and ATP release.

Area of Science:

  • Neuroimmunology
  • Cellular Neuroscience
  • Neuropharmacology

Background:

  • Microglia, the brain's immune cells, exhibit complex signaling and phagocytic behaviors.
  • Adenosine triphosphate (ATP) acts as a chemoattractant for microglia.
  • In the nucleus accumbens (NAc), ATP is co-released with dopamine (DA), and microglia possess receptors for both.

Purpose of the Study:

  • To investigate microglia chemotactic motility towards dopamine (DA) and adenosine triphosphate (ATP) in the NAc.
  • To examine the impact of reactive oxygen species (ROS) and immune activation on microglia and neurotransmitter release.

Main Methods:

  • Utilized iontophoresis and multiphoton microscopy in NAc brain slices from GFP-monocyte labeled transgenic mice.
  • Administered glucose oxidase to induce reactive oxygen species (ROS) and lipopolysaccharide (LPS) as a toll-like receptor 4 (TLR4) agonist.
  • Assessed microglia morphology, motility, and neurotransmitter release (DA and ATP).

Main Results:

  • ATP more consistently attracted microglia than DA; DA attraction was observed in a small subset and blocked by D1 antagonism.
  • Glucose oxidase increased ROS, altered microglial morphology/motility, decreased DA release, and had variable effects on ATP release.
  • LPS induced a transition from ramified to amoeboid microglia morphology and increased both DA and ATP release over 4 hours.

Conclusions:

  • Microglia exhibit differential chemotactic responses to ATP and DA in the NAc.
  • Immune activation, mediated by ROS or LPS, significantly impacts microglial behavior and neurotransmitter dynamics.
  • These findings underscore the intricate interplay between neuroinflammation and dopaminergic terminal function.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...